Logo image of GRFS

GRIFOLS SA-ADR (GRFS) Stock Fundamental Analysis

NASDAQ:GRFS - Nasdaq - US3984384087 - ADR - Currency: USD

7.45  -0.08 (-1.06%)

After market: 7.5 +0.05 (+0.67%)

Fundamental Rating

5

Taking everything into account, GRFS scores 5 out of 10 in our fundamental rating. GRFS was compared to 572 industry peers in the Biotechnology industry. GRFS has a medium profitability rating, but doesn't score so well on its financial health evaluation. A decent growth rate in combination with a cheap valuation! Better keep an eye on GRFS.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

GRFS had positive earnings in the past year.
GRFS had a positive operating cash flow in the past year.
GRFS had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: GRFS reported negative operating cash flow in multiple years.
GRFS Yearly Net Income VS EBIT VS OCF VS FCFGRFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

1.2 Ratios

Looking at the Return On Assets, with a value of 0.71%, GRFS belongs to the top of the industry, outperforming 93.07% of the companies in the same industry.
The Return On Equity of GRFS (2.69%) is better than 93.96% of its industry peers.
The Return On Invested Capital of GRFS (4.34%) is better than 94.49% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for GRFS is significantly below the industry average of 14.04%.
The last Return On Invested Capital (4.34%) for GRFS is above the 3 year average (2.88%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.71%
ROE 2.69%
ROIC 4.34%
ROA(3y)0.74%
ROA(5y)2.06%
ROE(3y)2.64%
ROE(5y)6.6%
ROIC(3y)2.88%
ROIC(5y)4.05%
GRFS Yearly ROA, ROE, ROICGRFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 5 10 15

1.3 Margins

GRFS has a Profit Margin of 2.05%. This is amongst the best in the industry. GRFS outperforms 93.61% of its industry peers.
GRFS's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 14.26%, GRFS belongs to the best of the industry, outperforming 95.74% of the companies in the same industry.
GRFS's Operating Margin has declined in the last couple of years.
The Gross Margin of GRFS (38.79%) is better than 76.38% of its industry peers.
GRFS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 14.26%
PM (TTM) 2.05%
GM 38.79%
OM growth 3Y-15.14%
OM growth 5Y-12.82%
PM growth 3Y-57.33%
PM growth 5Y-41.65%
GM growth 3Y-3.59%
GM growth 5Y-3.69%
GRFS Yearly Profit, Operating, Gross MarginsGRFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30 40

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GRFS is destroying value.
GRFS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRFS Yearly Shares OutstandingGRFS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
GRFS Yearly Total Debt VS Total AssetsGRFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B 20B

2.2 Solvency

GRFS has an Altman-Z score of 1.16. This is a bad value and indicates that GRFS is not financially healthy and even has some risk of bankruptcy.
GRFS's Altman-Z score of 1.16 is fine compared to the rest of the industry. GRFS outperforms 67.67% of its industry peers.
The Debt to FCF ratio of GRFS is 47.11, which is on the high side as it means it would take GRFS, 47.11 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of GRFS (47.11) is better than 92.36% of its industry peers.
A Debt/Equity ratio of 1.65 is on the high side and indicates that GRFS has dependencies on debt financing.
GRFS has a worse Debt to Equity ratio (1.65) than 82.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.65
Debt/FCF 47.11
Altman-Z 1.16
ROIC/WACC0.72
WACC6.03%
GRFS Yearly LT Debt VS Equity VS FCFGRFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 2.26 indicates that GRFS has no problem at all paying its short term obligations.
GRFS's Current ratio of 2.26 is on the low side compared to the rest of the industry. GRFS is outperformed by 74.25% of its industry peers.
A Quick Ratio of 0.79 indicates that GRFS may have some problems paying its short term obligations.
GRFS has a Quick ratio of 0.79. This is amonst the worse of the industry: GRFS underperforms 90.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.26
Quick Ratio 0.79
GRFS Yearly Current Assets VS Current LiabilitesGRFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 162.50% over the past year.
The earnings per share for GRFS have been decreasing by -36.48% on average. This is quite bad
The Revenue for GRFS has decreased by -13.25% in the past year. This is quite bad
The Revenue has been growing slightly by 8.00% on average over the past years.
EPS 1Y (TTM)162.5%
EPS 3Y-53.58%
EPS 5Y-36.48%
EPS Q2Q%0%
Revenue 1Y (TTM)-13.25%
Revenue growth 3Y7.27%
Revenue growth 5Y8%
Sales Q2Q%12.24%

3.2 Future

Based on estimates for the next years, GRFS will show a very strong growth in Earnings Per Share. The EPS will grow by 27.20% on average per year.
GRFS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.61% yearly.
EPS Next Y14.73%
EPS Next 2Y37.48%
EPS Next 3Y33.21%
EPS Next 5Y27.2%
Revenue Next Year8.13%
Revenue Next 2Y8.33%
Revenue Next 3Y7.9%
Revenue Next 5Y7.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
GRFS Yearly Revenue VS EstimatesGRFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
GRFS Yearly EPS VS EstimatesGRFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0.5 1 1.5 2

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 33.86, GRFS can be considered very expensive at the moment.
Based on the Price/Earnings ratio, GRFS is valued cheaper than 94.49% of the companies in the same industry.
GRFS's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 29.63.
Based on the Price/Forward Earnings ratio of 7.85, the valuation of GRFS can be described as very cheap.
GRFS's Price/Forward Earnings ratio is rather cheap when compared to the industry. GRFS is cheaper than 98.22% of the companies in the same industry.
GRFS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.68.
Industry RankSector Rank
PE 33.86
Fwd PE 7.85
GRFS Price Earnings VS Forward Price EarningsGRFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GRFS is valued cheaper than 98.05% of the companies in the same industry.
GRFS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GRFS is cheaper than 95.56% of the companies in the same industry.
Industry RankSector Rank
P/FCF 23.13
EV/EBITDA 9.58
GRFS Per share dataGRFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GRFS does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of GRFS may justify a higher PE ratio.
A more expensive valuation may be justified as GRFS's earnings are expected to grow with 33.21% in the coming years.
PEG (NY)2.3
PEG (5Y)N/A
EPS Next 2Y37.48%
EPS Next 3Y33.21%

More info and screens

0

5. Dividend

5.1 Amount

GRFS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRIFOLS SA-ADR

NASDAQ:GRFS (2/21/2025, 8:24:28 PM)

After market: 7.5 +0.05 (+0.67%)

7.45

-0.08 (-1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07
Earnings (Next)02-26 2025-02-26/amc
Inst Owners33.7%
Inst Owner Change-94.13%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap5.06B
Analysts74.29
Price Target14.18 (90.34%)
Short Float %1.1%
Short Ratio3.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.34%
PT rev (3m)-6.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.41%
EPS NY rev (1m)-17.21%
EPS NY rev (3m)-24.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)0.5%
Valuation
Industry RankSector Rank
PE 33.86
Fwd PE 7.85
P/S 0.69
P/FCF 23.13
P/OCF 9.18
P/B 0.9
P/tB N/A
EV/EBITDA 9.58
EPS(TTM)0.22
EY2.95%
EPS(NY)0.95
Fwd EY12.73%
FCF(TTM)0.32
FCFY4.32%
OCF(TTM)0.81
OCFY10.89%
SpS10.79
BVpS8.24
TBVpS-8.17
PEG (NY)2.3
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.71%
ROE 2.69%
ROCE 5.57%
ROIC 4.34%
ROICexc 4.54%
ROICexgc 12.03%
OM 14.26%
PM (TTM) 2.05%
GM 38.79%
FCFM 2.99%
ROA(3y)0.74%
ROA(5y)2.06%
ROE(3y)2.64%
ROE(5y)6.6%
ROIC(3y)2.88%
ROIC(5y)4.05%
ROICexc(3y)3.17%
ROICexc(5y)4.53%
ROICexgc(3y)7.26%
ROICexgc(5y)10.37%
ROCE(3y)3.7%
ROCE(5y)5.2%
ROICexcg growth 3Y-14.66%
ROICexcg growth 5Y-19.7%
ROICexc growth 3Y-16.79%
ROICexc growth 5Y-15.57%
OM growth 3Y-15.14%
OM growth 5Y-12.82%
PM growth 3Y-57.33%
PM growth 5Y-41.65%
GM growth 3Y-3.59%
GM growth 5Y-3.69%
F-Score6
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 1.65
Debt/FCF 47.11
Debt/EBITDA 6.17
Cap/Depr 73.42%
Cap/Sales 4.54%
Interest Coverage 250
Cash Conversion 36.8%
Profit Quality 145.3%
Current Ratio 2.26
Quick Ratio 0.79
Altman-Z 1.16
F-Score6
WACC6.03%
ROIC/WACC0.72
Cap/Depr(3y)72.34%
Cap/Depr(5y)93.22%
Cap/Sales(3y)3.24%
Cap/Sales(5y)4.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.5%
EPS 3Y-53.58%
EPS 5Y-36.48%
EPS Q2Q%0%
EPS Next Y14.73%
EPS Next 2Y37.48%
EPS Next 3Y33.21%
EPS Next 5Y27.2%
Revenue 1Y (TTM)-13.25%
Revenue growth 3Y7.27%
Revenue growth 5Y8%
Sales Q2Q%12.24%
Revenue Next Year8.13%
Revenue Next 2Y8.33%
Revenue Next 3Y7.9%
Revenue Next 5Y7.61%
EBIT growth 1Y18.07%
EBIT growth 3Y-8.97%
EBIT growth 5Y-5.84%
EBIT Next Year93.72%
EBIT Next 3Y35.2%
EBIT Next 5Y24.91%
FCF growth 1Y-7.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-332.44%
OCF growth 3YN/A
OCF growth 5YN/A